Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,770.51 74.50 0.33%

Omeros is Not Aware of Any Justification for Share Price Movement



      Omeros is Not Aware of Any Justification for Share Price Movement

PR Newswire

SEATTLE, Nov. 13, 2012

SEATTLE, Nov. 13, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) has
noted the fall in its share price over the last week of trading.  Omeros is
not aware of any reason that justifies this decrease. As disclosed in Omeros'
recent press releases and its Quarterly Report on Form 10-Q filed on November
9, 2012 with the US Securities and Exchange Commission, Omeros' business,
including its clinical programs and its preclinical pipeline, remains on track
and the Company is pleased with its progress.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates are derived from its proprietary PharmacoSurgery™
platform designed to improve clinical outcomes of patients undergoing a wide
range of surgical and medical procedures. Omeros has four ongoing clinical
development programs. Omeros may also have the near-term capability, through
its GPCR program, to add a large number of new drug targets and their
corresponding compounds to the market. Behind its clinical candidates and GPCR
platform, Omeros is building a diverse pipeline of protein and small-molecule
preclinical programs targeting inflammation, coagulopathies and central
nervous system disorders.

SOURCE Omeros Corporation

Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor
and Media Relations, +1-360-668-3701, jennifer@cwcomm.org
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement